SOUTH SAN FRANCISCO, Calif. & TOKYO--(BUSINESS WIRE)--Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO) and a leader in automated cell therapy manufacturing, and ...
CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--LumaCyte, a leader in advanced cellular analysis and precision bioanalytics, proudly announces the launch of its groundbreaking cell therapy application for ...
Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...
What is the current status of cell therapies today? It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the ...
Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results